Artikel: [Prospective comparison of cognitive and mpMR/US fusion biopsy for prostate cancer detection].
Urologiia (Moscow, Russia : 1999)
2022 , Heft 4, Seite(n) 38–43
Abstract: Introduction: According to the recommendations of the European Association of Urology the presence of a suspicious lesion on MRI is an indication for both primary and secondary MR-targeted biopsies. At the same time, the Russian Society of Urologists ... ...
Abstract | Introduction: According to the recommendations of the European Association of Urology the presence of a suspicious lesion on MRI is an indication for both primary and secondary MR-targeted biopsies. At the same time, the Russian Society of Urologists recommends to perform mpMR/US fusion biopsy only in patients with a prior negative biopsy. In clinical practice, mpMR/US fusion and cognitive biopsies are the most frequently performed. However, when comparing them, contradictory data on detection of clinically significant prostate cancer is obtained. Objective: to compare the detection rate of clinically significant prostate cancer performing cognitive and mpMR/US fusion biopsies. Materials and methods: Inclusion criteria: PSA >2 ng/mL and/or a positive DRE, and/or a suspicious lesion on TRUS, and PI-RADSv2.1 lesion more or equal 3. At first, "unblinded" urologist performed a transperineal mpMR/ultrasound fusion and saturation biopsy. Then "blinded" urologist obtained transrectal cognitive biopsy Clinically significant cancer was defined as ISUP more or equal 2. Results: We enrolled 96 patients. Median age was 63 years, prostate volume - 47 cm3 and PSA - 6.82 ng/mL. MpMR/US fusion and cognitive biopsies were comparable in regard to the detection rate of clinically significant (32.3% vs 25.0%; p=0.264), clinically insignificant cancer (25.0% and 26.0%; p=0.869) and overall detection rate (57.3% and 51%;p=0.385). Both biopsies missed clinically significant cancer with equal frequency (5.2%; p=0.839). Histological efficacy also was comparable. The number of positive cores between mpMR/US fusion and cognitive biopsy was equal (34.1% and 31.1% respectively; p= 0.415). At the same time, no statistically significant difference was found with respect to maximum cancer core length (53.1% vs 47.7%, respectively; p=0.293). Conclusion: The results suggest that both cognitive and mpMR/US fusion biopsies are equally accurate diagnostic methods for clinically significant prostate cancer detection, thus their wider introduction into clinical practice is necessary. |
---|---|
Mesh-Begriff(e) | Cognition ; Humans ; Image-Guided Biopsy/methods ; Male ; Middle Aged ; Prostate/diagnostic imaging ; Prostate/pathology ; Prostate-Specific Antigen ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology |
Chemische Substanzen | Prostate-Specific Antigen (EC 3.4.21.77) |
Sprache | Russisch |
Erscheinungsdatum | 2022-09-01 |
Erscheinungsland | Russia (Federation) |
Dokumenttyp | Journal Article |
ZDB-ID | 43204-0 |
ISSN | 1728-2985 ; 0042-1154 |
ISSN | 1728-2985 ; 0042-1154 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.B 1177: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.